Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Earnings for Nuvalent, Inc. (NUVL)
Earnings in 2023 (TTM): $-126,219,000
According to Nuvalent, Inc.'s latest financial reports the company's current earnings (TTM) are $-126,219,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Nuvalent, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-126,219,000 | $-126,219,000 |
| 2022 | $-81,854,000 | $-73,346,000 |
| 2021 | $-46,338,000 | $-46,338,000 |
| 2020 | $-14,556,000 | $-14,556,000 |
| 2019 | $-11,809,000 | $-11,809,000 |